OPKO launches new imaging device and kicks off trial

Article

OPKO Health, Inc has received FDA marketing clearance on an imaging device and launched clinical trials of a new glaucoma shunt, the company has announced.

OPKO Health, Inc has received FDA marketing clearance on an imaging device and launched clinical trials of a new glaucoma shunt, the company has announced.

The Spectral OCT SLO Combination Imaging System, which is already available in Europe, is now also available for marketing in the US, following receipt of FDA 510(k) clearance. The diagnostic device, for non-contact, non-invasive tomographic and confocal imaging, produces high resolution images of the inner retinal choroid with vitreous detail. It is indicated for in vivo viewing, axial cross-sectional, and three-dimensional imaging and measurement of posterior ocular structures including the retina, macula, retina nerve fibre layer and optic disc; altering the focal position allows the device to image the cornea, sclera and conjunctiva.

OPKO has also initiated clinical trials of the Aquashunt, a shunt to treat refractory open-angle glaucoma by providing an exit for excess fluid in the eye thereby reducing intraocular pressure (IOP). The Aquashunt has been implanted in the first human patients of its multicentre clinical trials, which will enrol up to 20 patients with significantly impaired visual acuity. The trials are designed to assess safety and efficacy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
© 2025 MJH Life Sciences

All rights reserved.